How Should CVD Risk be Assessed in Rheumatoid Arthritis?
Q&A: Two experts discuss proposals for formal CVD risk calculators in RA and the need for long-term research to validate them.
Dead Cells, Disrupted Lysosomes and Lupus
In this Q&A, Rheumatology Network speaks with Dr. Barbara Vilen who is making strides in both basic and translational research that may lead to new therapeutic targets for lupus.
The Lupus Action Plan, Explained
In this Q&A, Rheumatology Network speaks with Dr. Stephen Katz about the NIAMS Action Plan for Lupus Research.
Research Spotlight: Biomarkers for Anti-TNF Therapy Response in RA
With the hope of wasting less time on medications doomed to fail, researchers are seeking biomarkers to predict a patient’s response to particular RA treatments.
The Most Common Reasons Driving Readmissions in TJA
Prem N. Ramkumar, M.D., the author of a recent analysis on readmission rates in TJA, speaks with Rheumatology Network about why readmission rates matter.
Monitoring Drug Levels Can Help Treatment Adherence
Adherence to lupus treatment can be less than ideal, says Dr. Michelle Petri of Johns Hopkins. This is why monitoring whole-blood hydroxychloroquine levels is an important part of treatment.
An Increased Risk of Dementia Possible in Lupus
In patients with CNS lupus, early evidence shows the presence of the development of dementia, says Dr. Yehuda Shoenfeld of Israel. "Lupus is a disease of young females, so it's not elderly females with dementia at this age."
By clicking Accept, you agree to become a member of the UBM Medica Community.